M
Mauricio Burotto
Researcher at University of Texas MD Anderson Cancer Center
Publications - 42
Citations - 2600
Mauricio Burotto is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Nivolumab. The author has an hindex of 10, co-authored 19 publications receiving 1146 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Toni K. Choueiri,Thomas Powles,Mauricio Burotto,Bernard Escudier,Maria T Bourlon,B. Zurawski,Victor M. Oyervides Juárez,James J. Hsieh,Umberto Basso,Amishi Yogesh Shah,Cristina Suárez,Alketa Hamzaj,Jeffrey C. Goh,Carlos Barrios,Martin Eduardo Richardet,C. Porta,Ruben Dario Kowalyszyn,Juan P. Feregrino,Jakub Żołnierek,David Pook,Elizabeth R. Kessler,Yoshihiko Tomita,Ryuichi Mizuno,Jens Bedke,Joshua Zhang,Matthew Maurer,Burcin Simsek,Flavia Ejzykowicz,Gisela Schwab,Andrea B. Apolo,Robert J. Motzer +30 more
TL;DR: Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma.
Journal ArticleDOI
Pseudoprogression and Immune-Related Response in Solid Tumors
TL;DR: Antibodies to PD-1 and PD-L1 have shown potential clinical benefit in advanced solid tumors and drugs and additional immune checkpoint inhibitors are currently under investigation in multiple clinical trials as single-agent therapy and also in combination with other agents.
Journal ArticleDOI
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Laurence Albiges,Nizar M. Tannir,Mauricio Burotto,David F. McDermott,David F. McDermott,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Thomas Powles,Frede Donskov,Saby George,Christian Kollmannsberger,Howard Gurney,Howard Gurney,Marc-Oliver Grimm,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Toni K. Choueiri,Shruti Shally Saggi,M. Brent McHenry,Robert J. Motzer +21 more
TL;DR: NIVO+IPI continues to demonstrate durable efficacy benefits vs SUN, with manageable safety after long-term follow-up, and safety remained favourable with NIVO-IPI vs SUN.
Journal ArticleDOI
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins
Marianne S. Poruchynsky,Edina Komlodi-Pasztor,Shana Y. Trostel,Julia Wilkerson,Marie Regairaz,Yves Pommier,Xu Zhang,Tapan K. Maity,Robert W. Robey,Mauricio Burotto,Dan L. Sackett,Udayan Guha,Antonio Tito Fojo +12 more
TL;DR: DNA damage-repair proteins traffic on microtubules and addition of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.
Journal ArticleDOI
Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
TL;DR: Afatinib has similar efficacy compared with erlotinib and gefitinib in first-line treatment of tumors harboring EGFR mutations but may be associated with more toxicity, although further studies are needed.